Drug Discovery@nature.com 27 June 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 27 June 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter News Top Resurrected cancer drug faces regulators doi:10.1038/510454a Despite a chequered history, olaparib is finally before the US Food and Drug Administration. Full Text Sovaldi makes blockbuster history, ignites drug pricing unrest doi:10.1038/nbt0614-501 Gilead's $1,000-per-pill treatment for hepatitis C virus infections has ignited a pricing debate. Full Text The cancer-virus cures doi:10.1038/nm0614-571 On the fiftieth anniversary of the discovery that Epstein-Barr virus can cause cancer, researchers are considering joining up their experimental treatments against these malignancies. Full Text Trial watch: Lung cancer trial aims to bolster personalized medicine doi:10.1038/nrd4341 Cancer Research UK has teamed up with AstraZeneca and Pfizer to launch the National Lung Matrix Trial, which will test several targeted anticancer therapies in a single trial. Full Text Analysis Top Nav-i-gating antibodies for pain doi:10.1038/scibx.2014.662 Researchers are pursuing an antibody that blocks the Nav1.7 channel in a closed state for the potential treatment of pain and pruritus. Full Text Next-generation antibodies doi:10.1038/nrd4255 An overview of the different types of next-generation antibody therapeutics and an outlook of their market potential. Full Text Research Highlights Top Infectious disease: Small molecule combats measles virus doi:10.1038/nrd4343 An orally available small molecule that targets morbillivirus RNA polymerase might provide immunity against measles infection. Full Text Mitochondrial disease: Gene therapy protects heart in Friedreich's ataxia doi:10.1038/nrd4346 Study in mice shows gene therapy can prevent and even reverse cardiomyopathy in Friedreich's ataxia. Full Text Cancer: Turning glioblastoma cells vacuous doi:10.1038/nrd4345 Phenotypic screening identifies compounds that kill glioblastoma cells while sparing normal cells. Full Text Research & Reviews Top Liver X receptors in lipid metabolism: opportunities for drug discovery doi:10.1038/nrd4280 Hong and Tontonoz highlight tissue-specific aspects of LXR function with a focus on the liver, intestine and brain, and discuss the implications of advances in understanding LXR activity for drug development. Full Text HDL-targeted therapies: progress, failures and future doi:10.1038/nrd4279 In light of clinical trial failures of HDL-targeted therapies for cardioprotection, Kingwell and colleagues discuss the HDL hypothesis and consider strategies to address ongoing challenges for drug development. Full Text Targeting inflammation in the treatment of type 2 diabetes: time to start doi:10.1038/nrd4275 Donath describes the mechanisms underlying inflammation in type 2 diabetes and outlines the rationale for the use of anti-inflammatory agents. Full Text The amyloid state and its association with protein misfolding diseases doi:10.1038/nrm3810 A Review of the formation and molecular nature of amyloid species, and their role in both health and disease. Full Text Drug Discovery JOBS of the week Postdoctoral position in Polymer Chemist - Drug Discovery and Development Department Istituto Italiano di Tecnologia (IIT) Anticancer Drug Pharmacology Mount Sinai School of Medicine Postdoctoral Research Associate ? Cancer Drug Pharmacology University of Sydney Drug delivery researcher University of Limerick Cellular and Molecular Parasitology and Drug Discovery Inserm (French Institute of Health and Medical Research) More Science jobs from Drug Discovery EVENT 7th Imaging in Drug Discovery Conference 07.10.14 Dublin, Ireland More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.